Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;34(1):54-9.
doi: 10.5581/1516-8484.20120015.

Follicular lymphoma - treatment and prognostic factors

Stefano Luminari  1 , Monica Bellei, Irene Biasoli, Massimo Federico
Affiliations

Follicular lymphoma - treatment and prognostic factors

Stefano Luminari et al. Rev Bras Hematol Hemoter. 2012.

Abstract

Follicular lymphoma is the second most frequent non-Hodgkin lymphoma accounting for about 10-20% of all lymphomas in western countries. The median age at diagnosis is 60 years old. The clinical presentation is usually characterized by asymptomatic peripheral adenopathy in cervical, axillary, inguinal and femoral regions. Treatment options for patients with naïve or recurrent follicular lymphoma are still controversial, ranging from a "watch and wait" policy to hematopoietic stem cell transplantation. More recently, the availability of rituximab has substantially changed follicular lymphoma therapeutic approaches to such an extent that R-Chemo is now the standard induction first-line treatment. This review provides a general overview of the state of the art in the management of follicular lymphoma and also, a brief description regarding the current prognostic tools available for treatment decisions.

Keywords: Antibodies, monoclonal; Antineoplastic combined chemotherapy protocols/therapeutic use; Doxorubicin/therapeutic use; Lymphoma, follicular/drug therapy; Lymphoma, non-Hodgkin; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interest

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Armitage JO, Weisenburger DD.New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998; 16(8): 2780-95 - PubMed
    1. Freedman A.Follicular lymphoma: 2011 update on diagnosis and management. Am J Hematol. 2011; 86(9): 768-75 - PubMed
    1. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP.New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005; 23(33): 8447-52 - PubMed
    1. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006; 24(10): 1582-9 - PubMed
    1. van Oers MH, Kersten MJ.Treatment strategies in advanced stage follicular lymphoma. Best Pract Res Clin Haematol. 2011; 24(2): 187-201 - PubMed

LinkOut - more resources

  NODES
INTERN 2
Project 1
twitter 2